 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LYL845 / Lyell Immunopharma
Enrollment closed, Metastases: LYL845-101: A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov) - Nov 6, 2024
P1, N=108, Active, not recruiting, Sponsor: Lyell Immunopharma, Inc.
Recruiting --> Active, not recruiting
- || LYL845 / Lyell Immunopharma
Trial completion date, Trial primary completion date, Metastases: LYL845-101: A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov) - Dec 15, 2023
P1, N=108, Recruiting, Sponsor: Lyell Immunopharma, Inc.
- LYL845 / Lyell Immunopharma
Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1078;
P1
Exploratory objectives include measurement of tumor mutational burden, clonal diversity of the TIL drug product, T cell clonal expansion and persistence in the periphery and the presence of TIL drug product derived T cell clones in the tumor post-infusion. The trial is open and currently enrolling.
- ||| LYL845 / Lyell Immunopharma
Enrollment open, Metastases: LYL845-101: A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov) - Dec 21, 2022
P1, N=108, Recruiting, Sponsor: Lyell Immunopharma, Inc.
The trial is open and currently enrolling. Not yet recruiting --> Recruiting
- ||| LYL845 / Lyell Immunopharma
New P1 trial, Metastases: LYL845-101: A Study to Investigate LYL845 in Adults With Solid Tumors (clinicaltrials.gov) - Oct 10, 2022
P1, N=108, Not yet recruiting, Sponsor: Lyell Immunopharma, Inc.
- LYL845 / Lyell Immunopharma
The Epi-RTM technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_707;
Conclusions Results from research- and large-scale productions demonstrate that the Epi-R technology enables successful TIL expansion from both immunologically hot and cold tumors, while maintaining a greater proportion of stem-like T cells that demonstrate better metabolic fitness with preserved polyclonality (i.e., maintenance of tumor-reactive TCR diversity) across all 3 tumor types investigated. These findings support the clinical development of LYL845 in an upcoming first-in-human Phase 1 clinical trial.
- LYL845 / Lyell Immunopharma
The Epi-RTM technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_677;
Conclusions Pre-clinical data show that LYL845 is an expanded TIL product that preserves tumor-reactive clones with stem-like qualities. Based on these promising preclinical data, we plan to evaluate LYL845 for safety, tolerability, and anti-tumor activity in an upcoming first-in-human Phase 1 clinical trial.